4BASEBIO UK SOCIETAS (4BB) - Net Assets

Latest as of December 2025: GBX10.11 Million GBX ≈ $1.23K USD

Based on the latest financial reports, 4BASEBIO UK SOCIETAS (4BB) has net assets worth GBX10.11 Million GBX (≈ $1.23K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX29.55 Million ≈ $3.60K USD) and total liabilities (GBX19.44 Million ≈ $2.37K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 4BB strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX10.11 Million
% of Total Assets 34.22%
Annual Growth Rate N/A
5-Year Change -13.54%
10-Year Change N/A
Growth Volatility 31.2

4BASEBIO UK SOCIETAS - Net Assets Trend (2019–2025)

This chart illustrates how 4BASEBIO UK SOCIETAS's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 4BB company net worth.

Annual Net Assets for 4BASEBIO UK SOCIETAS (2019–2025)

The table below shows the annual net assets of 4BASEBIO UK SOCIETAS from 2019 to 2025. Also explore how fast is 4BASEBIO UK SOCIETAS growing its equity to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2025-12-31 GBX10.11 Million
≈ $1.23K		 -61.67%
2024-12-31 GBX26.38 Million
≈ $3.21K		 +5461.79%
2023-12-31 GBX-492.00K
≈ $-59.86		 -106.91%
2022-12-31 GBX7.12 Million
≈ $866.30		 -39.12%
2021-12-31 GBX11.70 Million
≈ $1.42K		 -24.34%
2020-12-31 GBX15.46 Million
≈ $1.88K		 +917.88%
2019-12-31 GBX-1.89 Million
≈ $-229.96		 --

Equity Component Analysis

This analysis shows how different components contribute to 4BASEBIO UK SOCIETAS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 4531700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock GBX13.80 Million 136.48%
Other Comprehensive Income GBX14.00 Million 138.42%
Other Components GBX37.25 Million 368.45%
Total Equity GBX10.11 Million 100.00%

4BASEBIO UK SOCIETAS Competitors by Market Cap

The table below lists competitors of 4BASEBIO UK SOCIETAS ranked by their market capitalization.

Company Market Cap
Aminex PLC
LSE:AEX
 $1.06 Million
Octopus Aim Vct Plc
LSE:OOA
 $1.06 Million
Grupo Famsa S.A.B. de C.V
MX:GFAMSAA
 $1.06 Million
Story-I Ltd
AU:SRY
 $1.07 Million
LUNGLIFE AI INC. DL-0001
F:9H4
 $1.06 Million
Marksmen Energy Inc
V:MAH
 $1.06 Million
Pacific Bay Minerals Ltd
V:PBM
 $1.06 Million
1Spatial PLC
LSE:SPA
 $1.05 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in 4BASEBIO UK SOCIETAS's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 26,380,000 to 10,111,000, a change of -16,269,000 (-61.7%).
  • Net loss of 16,905,000 reduced equity.
  • New share issuances of 31,000 increased equity.
  • Other comprehensive income decreased equity by 84,999.
  • Other factors increased equity by 689,999.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income GBX-16.91 Million -167.19%
Share Issuances GBX31.00K +0.31%
Other Comprehensive Income GBX-85.00K -0.84%
Other Changes GBX690.00K +6.82%
Total Change GBX- -61.67%

Book Value vs Market Value Analysis

This analysis compares 4BASEBIO UK SOCIETAS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 862.71x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2019-12-31 GBX-0.15 GBX562.50 x
2020-12-31 GBX1.25 GBX562.50 x
2021-12-31 GBX0.95 GBX562.50 x
2022-12-31 GBX0.58 GBX562.50 x
2023-12-31 GBX-0.04 GBX562.50 x
2024-12-31 GBX2.01 GBX562.50 x
2025-12-31 GBX0.65 GBX562.50 x

Capital Efficiency Dashboard

This dashboard shows how efficiently 4BASEBIO UK SOCIETAS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -167.19%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -998.52%
  • • Asset Turnover: 0.06x
  • • Equity Multiplier: 2.92x
  • Recent ROE (-167.19%) is below the historical average (-45.51%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2019 0.00% -209.41% 0.17x 0.00x GBX-234.00K
2020 -4.65% -155.63% 0.03x 1.15x GBX-2.26 Million
2021 -27.66% -957.10% 0.02x 1.26x GBX-4.40 Million
2022 -72.33% -1921.64% 0.02x 1.64x GBX-5.86 Million
2023 0.00% -1514.82% 0.04x 0.00x GBX-7.62 Million
2024 -46.75% -1321.86% 0.02x 1.70x GBX-14.97 Million
2025 -167.19% -998.52% 0.06x 2.92x GBX-17.92 Million

Industry Comparison

This section compares 4BASEBIO UK SOCIETAS's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $1,272,449
  • Average return on equity (ROE) among peers: -384.18%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
4BASEBIO UK SOCIETAS (4BB) GBX10.11 Million 0.00% 1.92x $1.06 Million
Aptamer Group PLC (APTA) $304.00K -2577.63% 8.06x $106.65K
Arecor Therapeutics PLC (AREC) $6.45 Million 10.29% 0.26x $401.97K
Avacta Group PLC (AVCT) $14.00K -764.29% 1.36x $3.99 Million
BSF Enterprise Plc (BSFA) $2.72 Million -40.97% 0.11x $14.84K
Bioventix (BVXP) $-71.00K 0.00% 0.00x $985.36K
Cizzle Biotechnology Holdings PLC (CIZ) $1.67 Million -80.55% 0.34x $77.17K
CRISM Therapeutics Corporation (CRTX) $15.21 Million -4.50% 0.05x $93.94K
Fusion Antibodies PLC (FAB) $323.00K 0.00% 1.18x $154.88K
Faron Pharmaceuticals Oy (FARN) $-15.16 Million 0.00% 0.00x $485.05K

About 4BASEBIO UK SOCIETAS

LSE:4BB UK Biotechnology
Market Cap
$1.06 Million
GBX8.71 Billion GBX
Market Cap Rank
#30654 Global
#800 in UK
Share Price
GBX562.50
Change (1 day)
+1.35%
52-Week Range
GBX435.00 - GBX795.00
All Time High
GBX1820.00
Categories
Companies in UK Biotechnology
About

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for u… Read more